Neuren Pharmaceuticals
Neuren Pharmaceuticals is a biopharmaceutical company focused on developing therapies for neurological conditions. The company is positioned in the biotechnology sector, leveraging its expertise in neuroscience to address unmet medical needs. Neuren's unique value lies in its targeted approach to treating rare neurological disorders, with a strong pipeline of innovative products.
Short position
Neuren Pharmaceuticals (ASX:NEU) has 2.95% of its shares on issue reported as short positions as of 5 Oct 2026, or about 3,735,393 shares. Over the past 30 days that figure has fallen 0.08 percentage points, and over 90 days it has fallen 1.96 percentage points. Its highest recorded short interest was 6.51% in June 2026. NEU is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Neuren Pharmaceuticals (NEU) company profile
Profile, insiders and operations
Company
AI-generated research profile of Neuren Pharmaceuticals
NEU intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links